A hematologist is a physician who specializes in diseases of the blood, bone marrow, and lymphatic system. Their scope ranges from common conditions like iron deficiency anemia to life-threatening blood cancers and rare inherited clotting disorders. Because blood touches every organ, the specialty sits at a crossroads of medicine, and hematologists frequently collaborate with surgeons, obstetricians, and other specialists to manage patients whose blood problems complicate other health issues.
Training and How Hematologists Differ From Other Doctors
Becoming a hematologist requires finishing medical school, completing a three-year residency in internal medicine (or pediatrics, for those treating children), and then entering a fellowship specifically focused on blood disorders. In the United States, that fellowship has traditionally been combined with oncology training, meaning many hematologists are also trained to treat solid-tumor cancers. This combined model has come under increasing scrutiny as both fields have grown more complex. A recent commentary in a major oncology journal argues that the combined fellowship is strained by accelerating subspecialization and recommends career-aligned tracks that let trainees develop deeper expertise in either hematology or oncology while still maintaining broad foundational knowledge.1PubMed Central. Toward Sustainable Hematology/Oncology Fellowship Training Through Career-Aligned Specialization
In practice, this means the hematologist you see might focus purely on non-cancerous blood conditions (sometimes called “benign hematology” or “classical hematology”), or they might split their time between blood cancers and other blood disorders, or they might work almost exclusively with cancer patients. It depends on the practice. In smaller hospitals and community clinics, one hematologist-oncologist often handles everything. In large academic medical centers, you are more likely to find physicians who have carved out narrow niches, such as hemophilia, sickle cell disease, or bone marrow transplantation.
How Hematologists Diagnose Blood Disorders
The starting point for almost every hematology workup is something most people have had drawn at a routine physical: a complete blood count, or CBC. This test reports counts and characteristics of the three major types of blood cells: red blood cells, white blood cells, and platelets. It also breaks down white blood cells into their subtypes. Abnormal results trigger alerts (called flags) that often prompt closer inspection.2Academic Press. The complete blood count and white blood cell differential Modern automated analyzers have largely replaced the older method of manually counting cells under a microscope as the first-pass screening tool.3PubMed. Peripheral blood film review. The demise of the eyecount leukocyte differential
When the CBC flags something unusual, the hematologist typically orders a peripheral blood smear, where a thin layer of blood is spread on a glass slide and examined under a microscope. This manual review provides the complete morphologic picture of a case and ensures that no significant finding is missed. A physician’s interpretation of the smear can offer a diagnosis or at least a strong diagnostic clue.4PubMed Central. Purpose and criteria for blood smear scan, blood smear examination, and blood smear review Cell shape, size, and color tell the trained eye a lot: fragmented red cells might signal a clotting problem inside blood vessels, while oversized red cells could point to a vitamin deficiency or a bone marrow disorder.
For deeper investigation, especially when blood cancers or bone marrow failure are suspected, a bone marrow aspiration and biopsy is often the next step. This procedure involves inserting a needle into a large bone (usually the back of the hip) to withdraw a small liquid sample of marrow and a tiny core of bone tissue. It is a key procedure for diagnosing blood cancers and for monitoring patients during chemotherapy or after a bone marrow transplant.5PubMed Central. A pathologist’s perspective on bone marrow aspiration and biopsy: I. Performing a bone marrow examination Using both the aspirate and the biopsy together gives hematologists the best picture, because the liquid sample shows individual cell detail while the solid core reveals how cells are distributed throughout the marrow. This combination is especially valuable in conditions like aplastic anemia, bone marrow cancers, and myeloproliferative disorders, where one technique alone might miss the full extent of the disease.6PubMed Central. Diagnostic value of bone marrow aspiration and biopsy in routine hematology practice
Anemia and Other Red Blood Cell Conditions
Anemia is by far the most common reason people land in a hematologist’s office. Not every anemic person needs a specialist; a primary care doctor can handle straightforward iron deficiency in most cases. The referral happens when the cause is unclear, when standard treatment fails, or when the anemia is severe or tied to a more complex underlying condition.
Iron deficiency and chronic inflammation are the two most frequent drivers of anemia, and distinguishing between them is a central task. Iron deficiency anemia results from depleted iron stores, whether from blood loss, poor absorption, inadequate diet, or increased demand such as during pregnancy. Anemia of inflammation, by contrast, occurs when the immune system diverts iron away from red blood cell production and locks it up in storage sites like the liver and spleen, effectively starving the bone marrow of the raw material it needs to build hemoglobin.7PubMed Central. Iron deficiency or anemia of inflammation? : Differential diagnosis and mechanisms of anemia of inflammation In the real world, both conditions can exist at the same time, making the detective work considerably harder. Hematologists rely on a panel of blood iron markers to sort this out; studies comparing these markers show that some traditional tests perform well but none alone is perfect for separating the two conditions.8American Journal of Clinical Pathology. Discriminating Between Iron Deficiency Anemia and Anemia of Chronic Disease Using Traditional Indices of Iron Status vs Transferrin Receptor Concentration
Beyond these acquired anemias, hematologists manage inherited red blood cell disorders. Thalassemia major and sickle cell disease are the two most widespread hereditary hemoglobin disorders worldwide. Both result from genetic mutations that produce abnormal hemoglobin, the oxygen-carrying protein in red cells. Advances in medical management have improved the outlook for affected individuals, but stem cell transplantation remains the only established cure.9PubMed Central. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel For sickle cell patients in particular, the disease imposes a heavy burden of painful episodes called vaso-occlusive crises and chronic complications such as bone damage and gallstones, all of which erode quality of life.10PubMed Central. A Cross-Sectional Study on the Quality of Life of Adults With Sickle Cell Disease Followed-Up in Outpatient Clinics: A Single-Center Experience
Bone Marrow Failure and White Blood Cell Disorders
When the bone marrow itself stops working properly, the consequences ripple across all blood cell lines. Aplastic anemia is one of the most serious examples. Despite the name, it is not a simple shortage of red cells. The marrow fails to produce enough red cells, white cells, and platelets, leaving a person vulnerable to infections, bleeding, and severe fatigue all at once. The underlying causes break down into three broad categories: direct injury to the marrow (from toxins, radiation, or certain drugs), immune-mediated destruction (where the body’s own immune system attacks marrow cells), and inherited or clonal bone marrow failure syndromes. Acquired immune aplastic anemia is the most common type, and treatment usually involves immunosuppressive therapy or, when a suitable donor exists, a stem cell transplant.11PubMed. Aplastic anaemia: Current concepts in diagnosis and management
White blood cell disorders also include a wide spectrum of conditions beyond marrow failure. Persistent unexplained high or low white cell counts are a frequent trigger for hematology referrals. Neutropenia, a low count of the most common infection-fighting white cells, accounted for roughly one in ten hematology referrals in one study of referral patterns.12Blood. Optimizing classical hematology referrals: Development and early evaluation of an enhanced referral intervention Sometimes the cause is benign and requires only monitoring; other times it signals something more concerning, from an autoimmune process to early leukemia. That uncertainty is a big part of why primary care doctors send these patients to a specialist.
Bleeding and Clotting Disorders
Blood’s ability to clot is a finely tuned system, and hematologists spend a lot of time with patients in whom that system is either too sluggish or too eager. On the bleeding side, von Willebrand disease is the most common inherited bleeding disorder. It is caused by defects in von Willebrand factor, a protein that acts as a kind of molecular glue, helping platelets stick to damaged blood vessel walls and also carrying clotting factor VIII in the bloodstream. When the protein is deficient or abnormal, factor VIII levels can drop as well, creating a dual problem with clotting. Treatment aims to correct both of these defects.13PubMed Central. Principles of care for the diagnosis and treatment of von Willebrand disease
Many people with von Willebrand disease go years without a diagnosis because the symptoms, such as heavy menstrual periods, easy bruising, or prolonged bleeding after dental work, are often dismissed as normal variation. A hematologist can run specialized coagulation tests that primary care labs typically do not offer, and then match the disease subtype to the right therapy, which can range from a nasal spray that boosts the body’s own von Willebrand factor to infusions of clotting factor concentrates.
On the other side of the spectrum sit thrombophilias, inherited or acquired tendencies to form blood clots too readily. Deep vein thrombosis and pulmonary embolism are the most feared consequences. One long-term study found inherited thrombophilia in about 28% of patients evaluated after a clotting event, and long-term anticoagulation was chosen for about 47% of those patients. Interestingly, the study found that the recurrence rate over more than two decades was similar in patients with and without an identified thrombophilia, and having an inherited clotting tendency did not significantly raise the risk of recurrence after stopping blood thinners.14PubMed. Predicting the risk of recurrent venous thromboembolism: Impact and therapeutic consequences of inherited thrombophilia Findings like these are why hematologists weigh each patient’s full clinical picture rather than relying on genetic test results alone when deciding how long someone should stay on anticoagulant medication.
Platelet Disorders
Platelets are the tiny cell fragments responsible for forming the initial plug at a bleeding site. Too few platelets (thrombocytopenia) can cause dangerous bleeding; too many (thrombocytosis) can paradoxically cause either clotting or bleeding. Among the conditions hematologists manage are immune thrombocytopenia, or ITP, in which the immune system destroys platelets faster than the marrow can produce them, and thrombotic thrombocytopenic purpura, or TTP, a rare but life-threatening emergency in which abnormal clotting in small blood vessels consumes platelets and shreds red blood cells.
TTP is caused by an antibody that attacks a specific enzyme needed to trim von Willebrand factor down to its normal size. Without that trimming, oversized strands of the protein trigger rampant clotting in tiny vessels throughout the body. The treatment, urgent plasma exchange, is highly specific and must begin quickly. Because TTP can mimic more common platelet conditions, hematologists sometimes use clinical scoring tools to identify it, even in patients whose demographics would otherwise make TTP seem unlikely.15PubMed Central. Sequential Immune Thrombocytopenia (ITP) and Thrombotic Thrombocytopenic Purpura (TTP) in an Elderly Male Patient with Primary Sjogren’s Syndrome: When in Doubt, Use the PLASMIC Score Thrombocytopenia was also among the top referring diagnoses to hematologists in a recent referral study, accounting for about 8% of classical hematology referrals.12Blood. Optimizing classical hematology referrals: Development and early evaluation of an enhanced referral intervention
Blood Cancers
Leukemia, lymphoma, and multiple myeloma are the three broad categories of blood cancer, and all fall squarely within hematology. Leukemias arise in the bone marrow and flood the blood with abnormal white cells. Lymphomas develop in the lymph nodes and lymphatic tissue. Multiple myeloma originates from plasma cells, a type of white blood cell that normally produces antibodies.
For myeloma, medical imaging plays a central role in staging and monitoring. Low-dose whole-body CT is now recommended over older X-ray surveys for detecting the bone disease that myeloma causes, and more advanced techniques like MRI and PET/CT are increasingly used.16PubMed Central. Multiple Myeloma Associated Bone Disease MRI is considered the most sensitive tool for initial staging, while PET/CT is particularly useful for tracking treatment response.17PubMed Central. Imaging of multiple myeloma: Current concepts A related condition, monoclonal gammopathy, was the second most common reason for hematology referral in one recent study, representing about 22% of referrals.12Blood. Optimizing classical hematology referrals: Development and early evaluation of an enhanced referral intervention Monoclonal gammopathy is not cancer, but it can progress to myeloma over time, so hematologists monitor these patients long-term.
Pediatric blood cancers, particularly acute lymphoblastic leukemia (ALL), deserve a mention because they highlight a specific wrinkle in hematology care. Children and adolescents with ALL have historically done better on pediatric treatment protocols than on adult ones. A Swedish study comparing the two approaches in patients over ten years of age found that the pediatric protocol achieved a remission rate of 99% compared with 90% for the adult protocol, with significantly better long-term outcomes as well.18PubMed. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol This finding has pushed adult hematologists to adopt more intensive, pediatric-inspired regimens for younger adult patients with ALL.
Stem Cell Transplants and Emerging Therapies
Hematopoietic stem cell transplantation, commonly known as a bone marrow transplant, is one of the most powerful tools in a hematologist’s arsenal. In this procedure, a patient’s diseased marrow is replaced with healthy stem cells, either from a matched donor (allogeneic transplant) or from the patient’s own previously collected cells (autologous transplant). Guidelines from the American Society for Blood and Marrow Transplantation categorize transplant indications along a spectrum, from well-established standard of care for diseases like certain leukemias and myeloma down to developmental indications where early-phase research shows promise but evidence is still limited.19PubMed Central. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
On the frontier, gene therapy is beginning to reshape the treatment of inherited blood disorders. CRISPR-based gene editing has moved from preclinical work into clinical trials for conditions like sickle cell disease, where the goal is to fix the underlying genetic defect in a patient’s own stem cells before returning them to the body.20Mary Ann Liebert, Inc., publishers. Progress, Applications and Prospects of CRISPR-Based Genome Editing Technology in Gene Therapy for Cancer and Sickle Cell Disease The first CRISPR-based therapy for sickle cell disease received regulatory approval in late 2023, marking a milestone for both hematology and the broader field of gene medicine. These treatments remain expensive and logistically demanding, requiring weeks of hospitalization and chemotherapy to prepare the marrow, so they are far from routine. But they represent a genuine shift toward curing diseases that have historically been managed rather than eliminated.
Transfusion Medicine
Blood transfusions are a daily reality in hospitals, and hematologists are often the physicians overseeing transfusion policies, managing complications, and consulting when unusual antibodies make finding compatible blood difficult. Transfusion-related complications fall into two broad time categories: acute reactions that develop within minutes to 24 hours and delayed reactions that can appear days, months, or even years later. Serious transfusion-related deaths are rare, estimated at about 0.26 per 100,000 transfusions, with circulatory overload, lung injury, and breathing difficulty accounting for about 60% of those fatalities. Overall adverse reactions of any kind occurred in only about 0.4% of transfused blood products in one retrospective study, and the most common were mild symptoms like restlessness, breathing difficulty, and chills.21PubMed Central. Ways To Enhance Blood Transfusion Safety: A Systematic Review
Despite those reassuring numbers, transfusion carries enough risk that hematologists push hard for “patient blood management” strategies that minimize unnecessary transfusions. This might mean using iron infusions to treat anemia before elective surgery, accepting lower hemoglobin thresholds before deciding to transfuse, or employing drugs that reduce surgical bleeding. Hematologists with transfusion medicine expertise also manage blood banks, ensuring proper testing, storage, and distribution of blood products.
When Hematology Overlaps With Other Specialties
Blood disorders rarely exist in isolation. A pregnant woman diagnosed with a blood cancer, for instance, poses treatment challenges that no single specialty can handle alone. International consensus guidelines for managing hematologic cancers during pregnancy recommend a multidisciplinary team that includes a hematologist-oncologist, a high-risk obstetrics specialist, a neonatologist, and experienced nurses and social workers.22PubMed. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting The hematologist’s role in these teams is to balance effective cancer treatment against risks to the developing baby, which often means adjusting drug choices and timing around trimesters.
Similar cross-specialty collaboration is common in orthopedic surgery (where patients with hemophilia need careful clotting-factor management), cardiology (where anticoagulant therapy intersects with heart conditions), and rheumatology (where autoimmune diseases cause blood abnormalities). A hematologist’s consultative role in these settings may never lead to a separate “hematology diagnosis,” but their input directly shapes treatment decisions.
What Drives Referrals to a Hematologist
If your primary care doctor sends you to a hematologist, the reason is most likely an abnormal blood count that needs further workup. One study of classical hematology referral patterns found that anemia was the top reason, accounting for about 31% of referrals, followed by monoclonal gammopathy at roughly 22%, iron deficiency at 10%, and low white cell counts (neutropenia) at about 10%. Platelet abnormalities, elevated iron markers, and hemoglobin disorders made up most of the remainder.12Blood. Optimizing classical hematology referrals: Development and early evaluation of an enhanced referral intervention
What surprises many patients is that a hematology referral does not automatically mean something is seriously wrong. A large share of referrals end up being conditions that are manageable with supplementation, monitoring, or minor medication changes. Monoclonal gammopathy, for example, is often a stable finding that simply needs periodic blood work to ensure it is not progressing. The hematologist’s job in those cases is less about treating an active disease and more about ruling out the dangerous possibilities and establishing a surveillance plan.
Living With a Chronic Blood Disorder
For patients who carry a long-term diagnosis, the impact extends well beyond blood counts. A study of patients with various blood disorders in Saudi Arabia found that financial stress scored highest among psychosocial burdens, followed by social exclusion and relationship challenges. Among quality-of-life measures, pain and reduced physical functioning were the most affected domains. The researchers also found strong links between social isolation and worsening general health.23PubMed. Quality of life and psychosocial impact on patients with blood disorders: An empirical study from patients’ perspectives in Saudi Arabia
Similar patterns emerge in specific disorders. People with chronic coagulation disorders like hemophilia report reduced quality of life compared to the general population, with the sharpest drops in general health, physical role limitation, and energy levels. One Australian study found that while family support was a clear positive in this population, school and workplace environments were areas where patients consistently faced challenges that deserve more attention.24PubMed. Health-related quality of life in chronic coagulation disorders Adults with sickle cell disease face an especially heavy burden; frequent pain crises and chronic complications like bone damage and gallstones significantly reduce quality of life, and comprehensive care models that include psychological support and pain management are increasingly seen as essential rather than optional.10PubMed Central. A Cross-Sectional Study on the Quality of Life of Adults With Sickle Cell Disease Followed-Up in Outpatient Clinics: A Single-Center Experience
These findings are reshaping how hematology practices operate. More clinics now embed social workers, mental health professionals, and patient navigators alongside physicians, recognizing that managing a blood disorder is not just about getting the lab values right. For patients, the practical takeaway is that it is reasonable to ask your hematology team about psychosocial resources, financial counseling, and pain management services, because these supports are becoming a standard part of hematologic care rather than extras you have to seek out on your own.